

Name Mark Peter de Caestecker
Address Division of Nephrology, Vanderbilt University School of Medicine
C3111, Medical Center North,
1161 21st Street South
Nashville, TN 37232-2372
Telephone 615 343 2844
Fax 615 343 2150
Date and Place of Birth July 16th 1958 at St. John and Elizabeth's Hospital, London, England
Citizenship British and US Citizen
Home Address 2610 Belcourt Avenue, Nashville, TN 37212
Cell Phone 615 512 4708
Family Widower
Children: Cassandra (DOB: 12/15/1984); Sebastien (DOB: 4/15/1986);
Christian (DOB: 07/15/1990); and Nathania (DOB: 06/13/1992)

Education

College

1977-1980 Peterhouse, Cambridge University, England
1980 B.A., (Cambridge)
Class 2.1 Med Sciences
Class 2.2 Part 1b Philosophy

Graduate Education

1980-1983 Middlesex Hospital, London
1983 M.B., B.S., (University College, London)
1984 M.A., (Cambridge)
1989-1993 University of Manchester, England
1993 Ph.D., (University of Manchester, Department of Medicine)
"Mononuclear cell activation and cytokine expression in human IgA nephropathy"

Postgraduate Training

Residency Equivalent

1984-1985 Senior House Officer, Intensive Therapy Unit, Middlesex Hospital, London
1985-1987 Medical SHO rotation Royal United & Royal National Rheumatology Hospitals, Bath
1987-1988 Registrar, Department of Medicine, St. Richards Hospital, Chichester, West Sussex, England
1988-1989 Registrar, Department of Medicine, Charring Cross Hospital, London

Fellowship Equivalent

1993-1995 Senior Registrar to Dr. Gokal, Dr. Ballardie, Dr. Short & Professor Mallick. Department of Nephrology and Medicine, Manchester Royal Infirmary

Research Fellowships and Mentors

1989-1993 North West Regional Health Authority Research Training Fellow Department of Nephrology and Medicine, Manchester Royal Infirmary. Supervisors: Dr. F.W. Ballardie

1995-1998 Wellcome Trust Advanced Clinical Training Fellowship in the Lab of Cell Regulation and Carcinogenesis, NCI, Bethesda, USA, under the supervision of Dr. Anita Roberts

1998-2000 Fogarty International Visiting Scientist, Laboratory of Cell Regulation and Carcinogenesis, NCI, Bethesda, USA, under the supervision of Dr. Anita Roberts

Licensure and Certification

1986 M.R.C.P. (Member of the Royal College of Physicians, United Kingdom)

1995 JCHMT accreditation in renal medicine (Nephrology Board Equivalent)

2000-present Distinguished Faculty Medical License (State of Tennessee)

Academic Appointments

1987-1989 Clinical Lecturer, Department of Medicine, Charring Cross Hospital, London.

1989-1993 North West Regional Health Authority Research Training Fellow, Department of Medicine,

1993-1995 Clinical Lecturer, Department of Medicine, Manchester University, England

1995-1998 Wellcome Trust Advanced Clinical Training Fellowship in the Laboratory of Cell Regulation and Carcinogenesis, NCI, Bethesda, USA

1998-2000 Fogarty International Visiting Scientist, Laboratory of Cell Regulation and Carcinogenesis, NCI, Bethesda, USA.

2000-9 Assistant Professor, Department of Medicine, Vanderbilt University Medical Center

2000-9 Assistant Professor, Department of Cancer Biology, Vanderbilt University

2002-9 Assistant Professor, Department of Cell and Developmental Biology, Vanderbilt University

2009-2011 Adjunct Professor, Middle Tennessee State University, TN

2009-2017 Associate Professor, Department of Medicine, Vanderbilt University Medical Center

2009-Present Associate Professor, Department of Surgery, Vanderbilt University Medical Center

2009-Present Associate Professor, Department of Cell and Developmental Biology, Vanderbilt University

2017-Present Professor, Department of Medicine, Vanderbilt University Medical Center

2017-Present Professor, Department of Surgery, Vanderbilt University Medical Center

Hospital Appointments

2002-Present Staff Physician (without compensation), Veterans Administration Hospital, Department of Internal Medicine, Nashville, TN

Professional Organizations

American Society of Nephrology

American Physiological Society

American Heart Association

Professional Activities

Intramural

2009-Present Cell and Developmental Biology Graduate Student Steering Committee Member

2014-Present Vanderbilt Institutional Animal Care and Use Committee (IACUC) Member

2017-Present Curriculum development committee for the Molecular Pathology and Immunology program

Peer Review Service at Vanderbilt

2003 Peer Review for the VUMC Discovery Grant Program

2004 Peer Review for VICC Breast Cancer SPORE pilot projects

2005 Peer Review for VICC Breast Cancer SPORE pilot projects

2010 Peer Review for O'Brien Kidney Injury and Physiology center pilot projects

2012-Present Peer review for Vanderbilt VCTRS and VPSD (K) Awards (Edge of Scholars program)

Extramural

Peer Review

2002 NIH/NIDDK: PPG and K18 Special Emphasis Review Panel

2003-2004 NIH/NIDDK K18 Special Emphasis Review

2004 Science Foundation of Ireland, Basic Research Grant Program, Ad Hoc Reviewer

2005 Cancer Molecular Biology Study Section R21 Ad Hoc

2007 NIH: UKGD Study Section, Ad Hoc member

Kidney Research UK, Research Grant Program, Member of the External Review Panel
Philip Morris External Research Program, External reviewer

2008 US-Israel Bi-national Science Foundation, reviewer

Research Grants Council of Hong Kong, reviewer

North West Cancer Research Fund (UK), reviewer

2009 NIH Special Emphasis Panel/Scientific Review Group ZRG1 CVRS-B (RIBT)

NIH EMNR IRG Study Section, Ad Hoc reviewer

2010 NIH Special Emphasis Panel/Scientific Review ZRG1 DKUS-B03

- Wellcome Trust (UK), Ad hoc reviewer
- 2010-Present American Society of Nephrology, Ad hoc Abstract Reviewer
- 2011 NIH Special Emphasis Panel/ SRG R24 PAR 08 181
 German-Israeli Foundation for Scientific Research, reviewer
 Kidney Research UK, Ad Hoc reviewer
 NIH Special Emphasis Panel/ ZHL1 CSR-Q
 Science Foundation of Ireland, Principal Investigator Program, Ad Hoc Reviewer
 Science Foundation of Ireland, Translational Research Awards, Ad Hoc Reviewer
 NIH RIBT Study Section, Ad Hoc member
- 2012 Children's Research Center of Michigan, External Grant Review
 American Heart Association Cardio-Renal-2 study section, Ad Hoc member
 Research Foundation – Flanders (FWO), Ad Hoc reviewer
- 2012-Present Respiratory Integrative Biology and Translational Research NIH Study Section, Member
- 2017 NIH PBKD Study Section, Ad Hoc member
 NIH Pediatric Nephrology Centers Special Emphasis Panel (ZDK1 GRB-1 (M2))
 NIH Nephrology Small Business Special Emphasis Panel (ZRG1 DKUS-L (11))
 American Society of Nephrology, Abstract Category Chair (Developmental Biology)

Advisory Committees and Consulting

- 2012 Medimmune Ventures (Astra Zeneca)
- 2014-2016 American Society of Nephrology Acute Kidney Injury Advisory Group
- 2014-2016 NephroGenex (Acute Kidney Injury Program)
- 2015 American Society of Nephrology Program Committee for ASN Kidney Week 2015
- 2016 Merck (Acute Kidney Injury Program)

Editorial Appointments and Journal Review

- 2013-Present Associate Editor BMC Nephrology
- 2015-Present Editorial board member AJP (Renal Physiology)

Ad Hoc Reviewer

Circulation Research, Circulation, PNAS, Nature Medicine, PLOS One, Biochemistry Journal, British Journal of Pharmacology, Development, Developmental Biology, Developmental Dynamics, Journal of Biological Chemistry, Oncogene, Human Molecular Genetics, Journal of Molecular Medicine, Journal of Molecular and Cellular Cardiology, Journal of Medical Genetics, Journal of Cell Science, Current Opinion in Pharmacology, FEBS letters, Kidney International, Journal of the American Society of Nephrology, American Journal of Pathology, Experimental Biology and Medicine, International Journal of Cancer, Laboratory Investigation, Nephrology Dialysis and Transplantation, BMC Molecular Biology, BMC nephrology, Bone, Cytokine and Journal of Biotechnology

Special Awards and Recognition

- 1989 Northwest Regional Training Fellowship

- 1995 Wellcome Trust Advanced Clinical Training Fellowship
- 1998 NIH Fellows Award for Research Excellence
- 2001 Outstanding Research Citation (VUMC)
- 2002 AHA Scientist Development Award (Declined)
- 2017 Fellow of the American Society of Nephrology

Teaching Activities

Medical School Courses

2015-present Co-Director, Vanderbilt University Medical School, Bench Research Immersion Program

Graduate School Courses

- 2007-2012 Director, “Cancer and Embryonic Development” three-hour credit graduate course CB10320/CANB320 (Dual listed-Cancer Biology/Cell & Developmental Biology)
- 2009-2012 Focus Group Leader, Interdisciplinary Graduate Program (IGP)
- 2011-Present Director, Vanderbilt Student Summer Research Training in Kidney Disease
- 2011-Present Director, Vanderbilt Mouse Kidney Injury Workshop
- 2012-2014 Director, HHMI Certificate Program in Molecular Medicine
- 2014-Present Director, Vanderbilt Program in Molecular Medicine
- 2014-Present Director, IGP Module: Introduction to Clinical and Translational Research

Clinical Teaching

2002-Present Medical Student Bedside Teaching (Nashville VA, Internal Medicine, 6-8 weeks/year)

Research Supervision

Graduate students mentored in the de Caestecker lab

- 2002-7 PhD Thesis Mentor for Scott Boyle (Cell and Developmental Biology). Currently staff pharmacist at Washington University
- 2002-6 PhD Thesis Mentor for David Frank (MSTP Student, Cell and Developmental Biology). Currently Assistant Professor of Pediatrics, The Perelman School of Medicine at University of Pennsylvania, Division of Pediatric Cardiology, Children's Hospital of Philadelphia
- 2006-10 PhD Thesis Mentor for Jonathon Lowery (Cell and Developmental Biology). Currently Assistant Professor of Physiology, Marian University College of Osteopathic Medicine
- 2009-10 M.Sc. Thesis Mentor for Mark Jones (MTSU). Currently family practice physician in East Tennessee
- 2009-13 Ph.D. Thesis Mentor for Andrea Frump (Cell and Developmental Biology). Currently post-doctoral fellow at the University of Indiana

- 2010-2016 Ph.D. Thesis Mentor for Takuto Chiba (Cell and Developmental Biology). Currently post-doctoral fellow at the University of Pittsburgh
- 2011-2016 Ph.D. Thesis Mentor for Allison Prewitt (Cell and Developmental Biology, American Heart Association Pre-Doctoral Fellow). Currently Medical Writer, Medpace, Cincinnati

Post-doctoral fellows mentored in the de Caestecker lab

- 2000-2007 Genbin Shi Ph.D. Currently Staff Scientist, Biomolecular Structure Section, National Cancer Institute at Frederick, MD
- 2001-2002 Zefan Ren Ph.D. Currently Professor, Department of Epidemiology, School of Public Health, Sun Yatsen University, Guangzhou, China
- 2002-2003 Xu-ping Wang Ph.D. Died 2012 while he was a post-doc with Dr. Ron Emeson at Vanderbilt
- 2002-2011 Harold Lovvorn M.D. (research mentor for Dr. Lovvorn's K99 award). Currently Associate Professor of Pediatric Surgery, Vanderbilt University School of Medicine.
- 2006-2009 Lynda Anderson Ph.D. (American Heart Association Post-doctoral fellow). Returning as a post-doc to the de Caestecker lab July 2017
- 2009-2013 Tatiana Noviskaya M.D., Ph.D. Currently post-doc with Andries Zijlstra at Vanderbilt
- 2011-2014 Sampa Ghose Ph.D. Currently CSIR Scientist, Jawaharlal Nehru University, New Delhi
- 2010-2016 Natalya Skrypnyk M.D. Currently a post-doc with Sarah Faubel, University of Colorado

Graduate Students and Interns rotating through the de Caestecker lab

- 2001 Scott Brittain (IGP), Alyssa Bonine (IGP), Peter Geissen (SLU, summer intern)
- 2002 Scott Boyle, David Frank, Karen McFarland (IGP), Monique Brink (Dutch Medical Student), Anne Tomlinson (1st year Medical Student, Georgetown University), Amir Abtahi (University of Miami, summer intern)
- 2003 Dean Yamaguchi (DJ) (2nd year Vanderbilt Medical Student), Soumyadeep (Shoumo) Dey (IGP), Melissa Harris (3rd year Vanderbilt Undergraduate), Michael Funk (High School Senior), Amir Abtahi (University of Miami, summer intern)
- 2004 Amir Abtahi (University of Miami, summer intern), Melissa Harris (3rd year Vanderbilt Undergraduate), Xi Zhang (IGP), Mingli Qi (IGP)
- 2005 Amir Abtahi (University of Miami, summer intern)
- 2006 Veronica Placencio (IGP), Stephen Kappa (Yale, Vanderbilt Undergraduate Clinical Research Internship Program)
- 2007 Erin Sparks (IGP)
- 2008 Julia Kutaka (MSTP), Bogdan Mazuruk (University of Amsterdam, Master of Oncology Program, Research Internship)
- 2009 Gabriella DiCarlo (1st year Vanderbilt Undergraduate, work study internship), Takuto Chiba (2nd year Graduate Student Department of Genetics)
- 2010 Patrice Wagner (IGP)

- 2011 Alison Prewitt (IGP), Evelyn Ozabache-Orrillo (University of Tennessee Health Sciences Center, 1st year medical student, Vanderbilt Summer Research Training Program)
- 2013 Kathy Zhang (Vanderbilt University, Undergraduate, Vanderbilt Summer Research Training Program and work study internship)
- 2014 Radostin Penchev (George Washington University, 1st year medical student, Vanderbilt Summer Research Training Program), Kathy Zhang (Vanderbilt University, Undergraduate, work study internship)
- 2015 Kevin Patel (Rosalind Franklin Medical School, 1st year medical student, Vanderbilt Summer Research Training Program)
- 2017 Bradley Mason (East Virginia Medical School, 1st year medical student, Vanderbilt Summer Research Training Program), Jackson Pearce (Furman University, Undergraduate Clinical Research Internship Program)

Ph.D. Qualifying Exam Committees

- 2002 Mark Sinnamon, Elizabeth Hamilton (Cancer Biology), and Yuki Ohi (Cell and Developmental Biology)
- 2003 Stephanie Duell (Cancer Biology)
- 2004 Roy Barco and Ritwick Gosh (Cancer Biology), Melissa Barty (Cell and Developmental Biology)
- 2005 Leta Moser and Tamela Hunt (Cancer Biology)
- 2006 Lindsay Bramson (Cell and Developmental Biology), Michael Casha (Cancer Biology)
- 2007 Edward Nam (Cancer Biology), Josh Smith (Cell and Developmental Biology)
- 2009 Kathryn Henley and Jarred Tanksley (Cell and Developmental Biology)
- 2010 Christopher Buckman and Julia Kutaka (Cell and Developmental Biology)
- 2011 Patrice Wagner (Chair, Cell and Developmental Biology)
- 2012 David Paik (Cell and Developmental Biology) and Lehanna Sanders (Chair, Cell and Developmental Biology)

Ph.D. Thesis committees

Nancy Dumont (2000-2002, Cancer Biology), William Tu (2001-2002, Cancer Biology), Yuki Ohi (2002-Cell and Developmental Biology), Mark Sundrud (2002-2005, Microbiology and Immunology), Melissa Langworthy (2004-2008, Cell and Developmental Biology), Roy Barco (2005-2008, Cancer Biology), Andres Rojas (2005-2008, Cancer Biology), Amanda Johnson (2005-2008, Microbiology and Immunology), Arunag Sarangi (2007-2009, Neurosciences); Josh Smith (2007-2010, Cell and Developmental Biology), Julia Kutaka (2010, Cell and Developmental Biology), Lindsay Bramson (2006-2010, Cell and Developmental Biology), Christopher Buckman (2010-2011, Cell and Developmental Biology), Debangshu Samanta (2010-2012, Cancer Biology), Kathryn Henley (2009-2013, Cell and Developmental Biology), Jarred Tanksley (2009-2013, Cell and Developmental Biology), Billy Carver (Chair, 2009-2013, Cell and Developmental Biology), David Paik (2012-2015, Cell and Developmental Biology), Lehanna Sanders (2012-2016, Chair, Cell and Developmental Biology); Patrice Wagner (Chair, 2011-2016, Cell and Developmental Biology); Carrie Weiss (2014-Present, MPB).

Other Significant Mentoring and Oversight Activities

- 2009-Present Cell and Developmental Biology Graduate Student Steering Committee Member
- 2011-2014 Scholarship Oversight Committee member, Angela Fagiana M.D., and Ben Mackowiak M.D., (Neonatology Training Fellow)
- 2015-Present Mentoring Committee for Lauren Woodard Ph.D., VA Career Development Award

Research Program

Grants

Currently Funded Grants

- 2013-2018 Short Term Research Training. 2T35 DK007383-34. PI: Alvin Powers. Role: Co-PI. ~2% effort
- 2016-2018 BMPR2-dependent metabolic reprogramming in pulmonary arterial hypertension. 16GRNT31310011. AHA Grant in Aid. Role: PI, \$70,000/year, ~8% effort
- 2016-2018 Persistent Six2 expression as a first hit mechanism of Wilms' tumorigenesis. 1R03CA182063-0. PI: Lovvorn. Role: Co-PI. ~2% effort
- 2017-2021 Mechanisms and therapeutic manipulation of retinoid acid signaling in acute kidney injury. 1R01DK112688-01A1. Role: PI, ~\$270,000/year, ~40% effort,
- 2017-2020 Optimizing small molecule therapeutics for diabetic kidney disease and AKI. PR161028. Role: PI, ~20% effort. MPI grant with University of Pittsburgh and Vanderbilt, \$3 million/year, ~\$275,000/year in direct costs to Vanderbilt, ~20% effort
- 2017-2022 O'Brien Vanderbilt Center for Kidney Disease. PI: Ray Harris. Role: Director of the Education and Enrichment Program, 10% effort

Completed Research Support

- 2014-2016 Regulation of Renal Progenitor Cells in Regenerating Kidneys. 3R01DK069403-05S1 de Caestecker (Co-Investigator) (R01 supplement: Hukriede (PI)), \$31,400/year, ~5% effort,
- 2014-2016 RA signaling in AKI. Pilot Project. VUMC44339-R/P30DK079307-07 Kleyman (PI), \$47,100/year, ~5% effort.
- 2014-2015 Use of a Novel PTBA Analogue to Ameliorate CKD Progression after AKI in Experimental Diabetic Nephropathy. Pilot Project. VUMC43321/U24 DK076169, \$100,000, ~10% effort,
- 2012-2015 HHMI MIG 56006779 de Caestecker (PI), Certificate Program in Molecular Medicine, ~10% effort
- 2012-2014 Mutation specific therapies in HPAH patients. R03 HL115112 de Caestecker (PI), \$78,000/year ~5% effort.
- 2010-2013 Small molecule augmented kidney regeneration. 1RC4DK090770-01. MPI grant: Hukriede-Pittsburgh/ de Caestecker-Vanderbilt. Role: PI, ~\$300,000/year in direct costs to Vanderbilt, ~40% effort.
- 2009-2014 BMP signaling and Pulmonary Vasoreactivity. R01 HL093057. Role: PI, \$250,000/year, ~40% effort.

- 2008-2013 Vanderbilt O'Brien Mouse Kidney Physiology and Disease Center. 1P30 DK07934
Role: Core Director, ~\$750,000/year, ~7% effort.
- 2009-2011 Conditional, Transposon-based Mutagenesis Screen for Wilms' Tumor-Associated Genes
5P30 DK079341-02S1. Principal Investigator., \$45,000 for 2 years, ~6% effort.
- 2009-2011 A mouse model of placental insufficiency with abnormal renal medullary patterning.
Principal Investigator. NIH 1R21 HD058302, \$150,000-year, ~ 20% effort.
- 2006-2009 BMP signaling and pulmonary hypertension in patients with COPD. Principal Investigator.
Philip Morris External Research Program Grant, \$175,000 per year for 3 years, ~20% effort.
- 2006-2007 Uteroplacental insufficiency and kidney development. Principal Investigator. NIH
(Pilot project for O'Brien Center Grant) \$40,000 per year, ~10% effort.
- 2005-2007 Cellular defects in familial pulmonary hypertension. Principal Investigator. NIH (1 R21
HL081167-01), \$150,000-year 1; \$125,000-year 2, ~20% effort.
- 2003-2004 Cell lineage tracing competitive supplement (R01 DK61558) \$70,000, ~5% effort
- 2002-2007 Transcriptional control of renal development by CITED1. Principal Investigator. NIH (R01
DK61558) \$225,000 per year for 5 years, ~40% effort.
- 2002-2004 Cited proteins in renal development and disease. Principal Investigator. NIH (Pilot project
for O'Brien Center Grant) \$40,000 per year for 2 years, ~10% effort.
- 2000-2002 The analysis of BMP type II receptor gene mutations in Familial Primary Pulmonary
Hypertension (FPPH). Vanderbilt University Medical Center Discovery Grant-I-040659320:
\$100,000, ~10% effort.
- 2000-2001 The role of MSG1 as a transcriptional regulator of blastemal differentiation in Wilms'
tumors. NCI Cancer Center Support Grant-1P30 CA68485: \$30,000, ~5% effort.

Publications

Original Articles Published in Refereed Journals

1. **de Caestecker MP**, Gower PE, Hall CL (1988). Differentiation of glomerular and non-glomerular haematuria. *Lancet* ii, 49-50
2. **de Caestecker MP**, Hall CL, Basterfield PJ, Smith JG (1989). Localisation of haematuria by red cell analysers and phase contrast microscopy. *Nephron* 52, 170-173
3. **de Caestecker MP**, Hall CL, McIvor AG.(1990). Atypical anti-glomerular basement membrane disease associated with thin membrane nephropathy: involvement of IgA and M isotypes. *NDT* 909-912
4. **de Caestecker MP**, Ballardie FW (1992). Volumetric analysis of urinary erythrocytes: a standardised methodology to localize the source of haematuria. *Am J Nephrol* 12, 41-8
5. **de Caestecker MP**, Telfer BA, Hutchinson IV, Ballardie FW (1992). The detection of intracytoplasmic IL-1a, IL-1b and TNF-a expression in human monocytes using two colour immunofluorescence flow cytometry. *J Immunological Methods* 154, 11-20
6. **de Caestecker MP**, Bottomley M, Telfer B, Hutchinson IV, Vose BM, Ballardie FW (1993). Detection of abnormal peripheral blood mononuclear cell cytokine networks in human IgA nephropathy. *Kidney International* 44: 1298-1308

7. Lechleider RJ, **de Caestecker MP**, Dehejia A, Polymeropoulos MH, Roberts AB (1996). Serine phosphorylation, chromosomal localization and TGF β signal transduction by human BSP-1. *J Biol. Chemistry* 271, 30: 17617-1762
8. **de Caestecker MP**, Hemmati P, Larisch-Bloch S, Ajmera R, Roberts AB, Lechleider RJ (1997). Characterization of functional domains within Smad4/ DPC4. *J Biol. Chemistry* 272, 21: 13690-13696
9. **de Caestecker MP**, Parks WT, Frank CJ, Castagnino P, DP, Roberts AB, Lechleider RJ. (1998) Smad2 transduces signals from receptor Serine-Threonine and Tyrosine kinases. *Genes and Development* 12, 1587-1592
10. Shioda T., Lechleider R., Dunwoodie S., Huchun L., Yahata T., **de Caestecker MP**, Fenner M., Roberts A., Isselbacher K. (1998). Transcriptional activating activity of Smad4: roles of Smad hetero-oligomerization and enhancement by an associating transactivator. *PNAS.U.S.A* 95, 9785-9790
11. Vindevoghel L., Lechleider R., Kon A., **de Caestecker M.**, Uitto J., Roberts A., Mauviel A. (1998) SMAD3/4-dependent transcriptional activation of the human type VII Collagen gene promoter *Proc.Natl.Acad.Sci.U.S.A* 95, 14769-14774
12. Ponclet AC, **de Caestecker MP**, Schnaper HW. (1999) TGF-b SMAD signaling pathway is present and functional in human mesangial cells. *Kidney International* 56(4), 1354-1365
13. **de Caestecker MP**, Wang D, Parks T, Shioda T, Hill C, Roberts A, Lechleider R. (2000) The Smad4 Activation Domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. *J Biol. Chemistry*, 275(03), 2115.
14. Yahata T, **de Caestecker MP**, Lechleider RJ, Andriole S, Roberts AB, Isselbacher KJ, Shioda T. (2000) MSG1 non-DNA binding transactivator enhances Smad-mediated transcription by interacting with p300/CBP co-activators. *J. Biol. Chemistry*, 275 (12), 8825-8834
15. Kim R, Wang D, Martin J, Huff C, **de Caestecker M**, Parks WT, Xianwang M, Lechleider RJ, Wang T, Roberts AR. (2000) A novel Smad Nuclear Interacting Protein (SNIP1) suppresses p300-dependent TGF-b signal transduction. *Genes & Development*, 14 (13), 1605-1616
16. Tsang M, Kim R, **de Caestecker M**, Kudoh T, Roberts A, Dawid IB. (2000). Zebrafish *nma* is involved in TGF-beta family signaling. *Genesis*, 28:47-57
17. Larisch-Bloch S, Youngsuk Yi, Lotan R, Kerner H, Eimerl S, Parks W, **de Caestecker M**, Danielpour D, Book-Melamed N, Timberg R, Lechleider R, Orly J, Kim S-J, Roberts A. (2000). A novel mitochondrial septin, ARTS, mediates TGF-b induced apoptosis via its P-loop motif. *Nature Cell Biology*, 2, 915-921
18. Dug-Keun Lee, Youngsuk Yi, Shin-Geon Choi, Cecile Lee, William T. Parks, HyeSeong Cho **Mark de Caestecker**, Yosef Shaul, Anita Roberts, Seong-Jin Kim (2001). The Hepatitis B virus pX amplifies TGF-b family signaling through direct interaction with Smad4: mechanism of HBV-associated hepatic cirrhosis. *Genes and Development*, 15 (4): 455-456
19. Chacko BM, Bin Y. Qin, John J. Correia, Suvana S. Lam, **Mark P. de Caestecker**, Kai Lin (2001). The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization. *Nature Structural Biology* 8, 248-253
20. Qin BY, Chacko BM, Lam SS, **de Caestecker MP**, Correia JJ, Lin K. Structural basis of Smad1 activation by receptor kinase phosphorylation. *Mol Cell*. 2001 Dec;8(6):1303-12.
21. Watanabe H, **de Caestecker M**, Yamada Y (2001). Transcriptional cross-talk between Smad, ERK1/2 and p38 MAPK pathways regulates TGF-b induced aggrecan gene expression in chondrogenic ATDC5 cells. *J. Biol. Chemistry, J Biol Chem*. 2001 Apr 27;276(17):14466-73.

22. W. Tony Parks, David Frank, Carla Huff, Carol R. Haft, Jennifer Martin, Xianwang Meng, **Mark P. de Caestecker**, James McNally, Amit Reddi, Simeon I. Taylor, Anita B. Roberts, T. Wang, Lechleider R.J. (2001). Sorting Nexin 6, a novel SNX, interacts with the TGF-beta family of receptor serine-threonine kinases. *J. Biol. Chemistry*, 276 (22) 19332-9
23. **de Caestecker MP**, Bottomley M, Bhattacharyya S, Payne T, Roberts A, Yelick P (2002). The novel type I serine-threonine kinase receptor Alk8 binds TGF-b In the presence of TGF-b RII. *Biochem Biophys Res Comm*, 293, 1556-1565
24. Hayashida T, **de Caestecker MP**, Schnaper HW (2003) The ERK MAP kinase enhances TGF-b stimulated Smad-activation in a cell type specific manner. *FASEB Journal* 17(11): 1576-8
25. Benoy Chacko, Bin Y. Qin, Ashutosh Tiwari, Genbin Shi, Suvana Lam, Lawrence J. Hayward, **Mark de Caestecker**, and Kai Lin. Structural Basis of Heteromeric Smad Protein Assembly in TGF-b Signaling. (2004) *Molecular Cell* 15, 813-823
26. Sergei Plisov, Michael Tsang, Genbin Shi, Scott Boyle, Kiyoshi Yoshino, Sally Dunwoodie, Igor Dawid, Toshi Shioda, Alan Perantoni, **Mark de Caestecker**. Cited1 is a bi-functional transcriptional co-factor that regulates early nephronic patterning. *J Am Soc Nephrology*. 2005 Jun;16(6):1632-44.
27. Frank, D.B., Abtahi, A., Yamaguchi, D.J., Manning, S., Shyr, Y., Pozzi, A., Baldwin, H.S., Johnson, J.E., and **de Caestecker, M.P.** Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. *Circulation Research*. 2005, Sept 2, 97:496-504.
28. Chen J., Boyle S., Zhao M., Su W., Takahashi K., Davis L., **de Caestecker M.**, Takahashi T., Breyer M., Hao C-M. Differential expression and localization of the intermediate filament protein Nestin during renal development and its localization in adult podocytes. *J Am Soc Nephrology* 2006 May;17(5):1283-91
29. Shi G.B., Boyle S., Sparrow D.B., Sally L. Dunwoodie S.L., Shioda T., **de Caestecker M.P.** The transcriptional activity of CITED1 is regulated by phosphorylation in a cell cycle dependent manner. *J. Biol Chemistry* 2006 Sep 15;281 (37):27426-35
30. Wang S., **de Caestecker M.**, Kopp J., Mitu G., Hirschberg R. Transgenic Renal Bone Morphogenetic Protein-7 protects against Diabetic Nephropathy. *J Am Soc Nephrology* 2006 Sept; 17 (9) 2504-2512
31. Lovvorn HN, Boyle S, Shi G, Shyr Y, Wills ML, Perantoni AO, **de Caestecker M.** Wilms' tumorigenesis is altered by mis-expression of the transcriptional co-activator, CITED1. *J Pediatric Surgery*, 42(3), 474-81, 2007
32. Boyle S, Shioda T, Perantoni AO, **de Caestecker M.** Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis. *Developmental Dynamics* 236(8):2321-30, 2007
33. Lovvorn HN, Westrup J, Opperman S, Boyle S, Shi G, Anderson J, Perlman EJ, Perantoni AO, Wills M, **de Caestecker MP.** CITED1 expression in Wilms' tumor and embryonic kidney. *Neoplasia* 9 (7): 589-600, 2007
34. Scott Boyle, Andrew Misfeldt, Kelly J. Chandler, Karen K. Deal, E. Michelle Southard-Smith, Douglas P. Mortlock, H. Scott Baldwin, and **Mark de Caestecker**. Fate mapping using *Cited1-CreER^{T2}* mice demonstrates that the cap mesenchyme contains self-renewing progenitor cells and gives rise exclusively to nephronic epithelia. *Developmental Biology* 313(1):234-245, 2008
35. David B. Frank, Jonathan Lowery, Lynda Anderson, Monique Brink, Jeff Reese, **Mark de Caestecker**. Increased susceptibility to hypoxic pulmonary hypertension in *Bmpr2* mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. *Am J Physiol Lung Cell Mol Physiol* 294(1):L98-L109, 2008

36. Langworthy M, Zhou B, **de Caestecker M.P.**, Moeckel G, Baldwin H.S. NFATc1 identifies a progenitor proximal tubule sub-population following HgCl₂ injury. *J Am Soc Nephrol*, 20 (2), 311-321, 2009
37. Sparrow D.B., Boyle S.C., Sams R.S., Mazuruk B., Zhang L., Moeckel G.W., Dunwoodie S.L., **de Caestecker M.P.** Placental insufficiency causes renal medullary dysplasia in *Cited1* mutant mice. *J Am Soc Nephrol*, 20 (4): 777-786, 2009
38. Lynda Anderson, Jonathan W. Lowery, David B. Frank, Mark Jones, Douglas P. Mortlock, Ronald L. Chandler and **Mark P. de Caestecker**. Opposing effects of Bmp2 and Bmp4 in hypoxic pulmonary hypertension. *Am J Physiol Reg, Int Comparative Physiol*, 2010 298(3):R833-42, 2010. PMID: 20042692
39. Ming-Zhi Zhang, Yinghao Su, Bing Yao, Wei Zheng, **Mark deCaestecker** and Raymond C. Harris. Assessing the Application of Tissue Microarray Technology to Kidney Research. *Histochemical J* 2010 May;58(5):413-20. PMID: 20086233
40. Jonathan W. Lowery, Andrea L. Frump, Lynda Anderson, Gabriella E. DiCarlo, Mark T. Jones, **Mark P. de Caestecker**. ID family protein expression and regulation in hypoxic pulmonary hypertension. *Am J Physiol Reg, Int Comparative Physiol* 2010 Dec;299(6):R1463-77 PMID: 20881097
41. Tatiana Novitskaya, Mariana Baserga, **Mark P. de Caestecker**. Organ-specific defects in insulin-like growth factor and insulin receptor signaling in late gestational asymmetric intrauterine growth restriction in *Cited1* mutant mice. *Endocrinology* 2011 Jun;152(6):2503-16. PMID: 21486933
42. Peter E. Clark, Dina Polosukhina, Harold Love, Hernan Correa, Cheryl Coffin, Elizabeth Perlman, **Mark de Caestecker**, Harold L. Moses, Roy Zent. β -catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms Tumors. *Am J Pathology* 2011 Dec; 179(6): 3045-55
43. Aaron C. Brown, Derek Adams, **Mark de Caestecker**, Xuehui Yang, Robert Friesel, and Leif Oxburgh. FGF/EGF signaling regulates renewal of early nephron progenitors during embryonic development. *Development* 2011 Dec; 138(23): 5099-112 PMID: 22031548
44. Murphy AJ, Axt JR, de Caestecker C, Pierce J, Correa H, Seeley EH, Caprioli RM, Newton MW, **de Caestecker MP**, Lovvorn HN: Molecular characterization of Wilms tumor from a resource-constrained region of sub-Saharan Africa. *Int J Cancer*. 2012 Sep 15;131(6):E983-94. PMID: 22437966
45. Murphy AJ, de Caestecker C, Pierce P, Boyle S, Ayers GD, Zhao Z, Correa H, Walter T, Huppert S, Perantoni AO, **de Caestecker MP**, Lovvorn HN. III, M.D. CITED1 activity in liver development and hepatoblastoma. *Neoplasia* Volume 14 Number 12 December 2012 pp. 1153–1163 1153. PMID: 23308048
46. Walker KA, Sims-Lucas S, Di Giovanni VE, Schaefer C, Sunseri WM, Novitskaya T, **de Caestecker MP**, Chen F, Bates CM. Deletion of fibroblast growth factor receptor 2 from the peri-wolffian duct stroma leads to ureteric induction abnormalities and vesicoureteral reflux. *PLoS One*. 2013;8(2):e56062. PMID: 23409123
47. Murphy AJ, Pierce J, de Caestecker C., Taylor C, Anderson JR, Perantoni A, **de Caestecker M**, Lovvorn HN. Six2 and Cited1, markers of nephronic progenitor self renewal remain active in primitive elements of Wilms' tumor. *J Pediatric Surgery* 2012 Jun;47(6):1239-49 PMID: 2270380
48. Skrypnik NI, R.C. Harris, **de Caestecker MP**. Ischemia-reperfusion model of acute kidney injury and post injury fibrosis in mice. *Vis Exp*. 2013 Aug 9;(78). PMID: 23963468
49. Cosentino CC, Skrypnik NI, Brill L, Chiba T, Novitskaya T, Woods C, West J, Korotchenko N, McDermott L, Day BW, Davidson AJ, Harris RC, **de Caestecker MP***, Hukriede NA*. A new HDAC

inhibitor enhances recovery after acute kidney injury. *J Am Soc Nephrol*. 2013 May;24(6):943-53
PMID: 23620402 *Joint senior authorship

50. Frump A.L., Lowery J.W., Hamid R., Austin E.D., **de Caestecker M.P.** Abnormal trafficking of endogenously expressed *BMP2* mutant allelic products in patients with Heritable Pulmonary Arterial Hypertension. *PLoS One*. 2013 Nov 5;8(11):e80319 PMID: 24224048
51. Tatiana Novitskaya T., McDermott L., Zhang K.X., Chiba T., Pauksakon P., Hukriede N.A., **de Caestecker M.P.** A PTBA class small molecule enhances recovery and reduces post injury fibrosis after aristolochic acid-induced kidney injury. *Am J Physiol Renal Physiol*. 2014 Mar 1;306(5):F496-504. PMID: 24370591
52. Murphy AJ, Pierce J, de Caestecker C, Ayers GD, Zhao A, Krebs JR, Kenyi Saito-Diaz C, Lee E, Perantoni AO, **de Caestecker M**, Lovvorn HN: *CITED1* confers stemness to Wilms tumor and enhances tumorigenic responses when enriched in the nucleus. *Oncotarget*. 2014 Jan 30;5(2):386-402. PMID: 24481423
53. Murphy AJ, Pierce J, de Caestecker C, Libes J, Neblett D, **de Caestecker M**, Perantoni AO, Tanigawa S, Anderson JR, Dome JS, Das A, Carroll TJ, Lovvorn HN 3rd. Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor. *Pediatr Blood Cancer*. 2014 Feb;61(2):198-205 PMID: 24115727
54. Mokkaapati S, Niopek K, Huang L, Cunniff KJ, Ruteshouser EC, **de Caestecker M**, Finegold MJ, Huff V. β -catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. *Cancer Res*. 2014 Aug 15;74(16):4515-25. PMID: 24848510
55. Pierce J, Murphy AJ, Panzer A, de Caestecker C, Ayers GD, Neblett D, Saito-Diaz K, **de Caestecker M**, Lovvorn HN 3rd. Six2 Effects in Wilms' tumor biology. *Transl Oncol*. 2014 Dec;7(6):800-11. PMID: 25500091
56. Prewitt AR, Ghose S, Frump AL, Datta A, Austin ED, Kenworthy AK, **de Caestecker MP**. Heterozygous Null Bone Morphogenetic Protein Receptor Type 2 Mutations Promote SRC kinase-dependent Caveolar Trafficking Defects and Endothelial Dysfunction in Pulmonary Arterial Hypertension. *J Biol Chem*. 2015 Jan 9;290(2):960-71. PMID: 25411245
57. Chiba T, Skrypnik NI, , Brilli-Skvarca L., Penchev R, Zhang KZ, Rochon ER, Fall JL, Pauksakon P, Yang H, Alford CE, Roman BL, Zhang MZ, Harris R, Hukriede NL, **de Caestecker MP**. Retinoic Acid Signaling Coordinates Macrophage-Dependent Injury and Repair after Acute Kidney Injury. *J Am Soc Nephrol* 2016 Feb;27(2):495-508. PMID:26109319
58. Skrypnik NI, Sanker S, Brilli-Skvarca L, Novitskaya T, Woods C, Chiba T, Patel, K Goldberg ND, McDermott L, Vinson PN, Calcutt MW, Huryn DM, Verneti LA, Vogt A, Hukriede N*, **de Caestecker MP***. Delayed treatment with PTBA analogs reduces post injury renal fibrosis after kidney injury. *AJP-renal*2016 Apr 15;310(8):F705-F716. PMID: 26661656
59. Skrypnik NI, Voziyan P, Yang H, de Caestecker CR, Theberge M-C, Drouin M, Hudson B, Harris RC, **de Caestecker MP**. Pyridoxamine reduces post-injury fibrosis and improves functional recovery after acute kidney injury. *AJP-renal* 2016 Aug 1;311(2):F268-77. PMID: 27194713
60. West JD, Voss BM, Pavliv L, **de Caestecker M**, Hemnes AR, Carrier EJ. Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload. *Pulmonary Circulation*. 2016 Jun;6 (2):211-23. PMID: 27252848
61. Frump AL, Datta A, Ghose S, West J, **de Caestecker M.P.** Genotype-phenotype effects of *Bmpr2* mutations on disease severity in mouse models of pulmonary hypertension. *Pulmonary Circulation*. 2016 Dec; 6(4):597-607. PMID: 28090303

Review Articles and Editorials

1. **de Caestecker MP**, Ballardie FW. Unexplained haematuria: may be due to slowly progressive glomerular disease Br Medical J 1990, 301, 1172-1173
2. Mallick NP, **de Caestecker MP**. The Changing population on renal replacement therapy: its clinical and economic impact in Europe. Nephrol Dial Transplant 1996, 11 Suppl 2: 2-5
3. Roberts AB, Lechleider RJ, **de Caestecker MP**, Ashcroft G, Yang X, Deng CX, Letterio J. Novel signal transduction pathways from TGF- β family of receptor serine-threonine kinases. Eur. Cytokine Network 1998, 9 (3), 548
4. **de Caestecker MP**, Piek E, Roberts AB. The role of TGF- β signaling in Cancer. J Natl. Cancer Institute 2000, 92 (17) 1388-1402
5. Roberts AB, Piek E, **de Caestecker MP**. Response: the role of TGF- β signaling in Cancer. J Natl. Cancer Institute 2001, 93 (7) 556-557
6. **de Caestecker M**, Meyrick B. Bone Morphogenetic proteins, genetics and pathophysiology of primary pulmonary hypertension. Respiratory Research 2001, 2, 193-7
7. **de Caestecker MP**. The Transforming Growth Factor beta Superfamily of Receptors. Cytokine and Growth Factor Reviews 2004, 15 (1) 1-11
8. **de Caestecker M.P.** Serotonin signaling in pulmonary hypertension. Circulation Research. 2006, 98(10):1229-31
9. Boyle S., **de Caestecker MP**. The role of transcriptional networks in coordinating early events in kidney development. American Journal of Renal Physiology 2006, 291, 1:8
10. **de Caestecker MP**. Angiopoietin-2 and proteinuria. J Am Soc Nephrology, 2007, 18: 2217-2218
11. Lowery J, **de Caestecker MP**. BMP signaling in Vascular Development and Disease. Cytokine and Growth Factor Reviews 2010 Aug;21(4):287-98
12. Swanhart LM, Cosentino CC, Diep CQ, Davidson AJ, **de Caestecker M**, Hukriede NA. Zebrafish kidney development: basic science to translational research. Birth Defects Res C Embryo Today. 2011 Jun;93(2):141-56. PMID: 21671354
13. Brill LL, Swanhart LM, **de Caestecker MP**, Hukriede NA. HDAC inhibitors in kidney development and disease. Pediatr Nephrol. 2013 Oct;28(10):1909-21. PMID: 23052657
14. Swanhart L., Cosentino C., Dipe C., Davidson A., **de Caestecker M.**, Hukriede N. Zebrafish Kidney Development: Birth Defects Res C Embryo Today. 2011 Jun;93(2):141-56
15. Leif Oxburgh, **Mark de Caestecker**. Ischemia Reperfusion Injury of the Mouse Kidney. Methods in Molecular Biology 2012;886:363-79 PMID: 22639277
16. Cirio MC, de Groh ED, **de Caestecker MP**, Davidson AJ, Hukriede NA. Kidney Regeneration: common themes from the embryo to the adult. Pediatr Nephrol. 2014 Apr;29(4):553-64. PMID: 24005792
17. Chiba T, Hukriede N, **de Caestecker M**. Kidney Regeneration: Lessons from Development. Current Pathobiology Reports, 2015; 3:67-79. PMID: 26120499
18. **Mark de Caestecker**, Ben D. Humphreys, Kathleen D. Liu, William H. Fissell, Jorge Cerda, Thomas D. Nolin, David Askenazi, Girish Mour, Frank E. Harrell Jr, Nick Pullen, Mark D. Okusa, Sarah Faubel.

Bridging Translation by Improving Preclinical Study Design for Acute Kidney Injury. J Am Soc Nephrology 2015 Dec;26(12):2905-16. PMID: 26538634

19. Skrypnik NI, Siskind LJ, Faubel S, **de Caestecker MP**. Bridging translation for acute kidney injury with better pre-clinical modeling of human disease. AJP-renal. 2016 May 15; 310(10): F972-84. PMID: 26962107
20. King T., **de Caestecker MP**, Lowery JW. Bone Morphogenetic protein contribution to pulmonary artery hypertension. Surg Neurol Int. 2016 Oct 19; 7:91. PMID: 27857855
21. Hukriede N, Vogt A, **de Caestecker MP**. Drug Discovery to Halt the Progression of AKI to CKD: a case for phenotypic drug discovery in AKI. Nephron Jun 15, 2017 [Epub ahead of print]. PMID: 28614822
22. Frump A, Prewitt A, **de Caestecker MP**. *BMP2* mutations and endothelial dysfunction in pulmonary arterial hypertension. Pulmonary Circ December 2017 [In press]
23. Translating knowledge into therapy for acute kidney injury. **de Caestecker MP**, Harris R. Seminars in Nephrology [In press]

Book Chapters

1. **de Caestecker MP**. Transforming Growth Factor beta Receptor Superfamily, in Encyclopedia of Biological Chemistry (W.J. Lennarz and M.D. Lane), Elsevier, Oxford, Volume 2004, 4, 209-214
2. Lowery J, **de Caestecker MP**. BMP signaling and Vascular Disease, in Encyclopedia of Biological Chemistry, Elsevier, Oxford, Volume 1, 229-239, 2013

Invited Presentations at Scientific Meetings (*international meetings highlighted in italics*)

- | | |
|------|---|
| 1992 | <i>University of Nottingham</i> |
| 1993 | <i>The Manchester Molecular Biology Group</i> |
| 1994 | <i>The Institute of Nephrology, Department of Medicine, Cardiff University</i> |
| 1997 | <i>i) British Renal Association Autumn Meeting, London
ii) Institute of Medical Sciences, Aberdeen, Scotland
iii) School of Biological Sciences, Manchester University</i> |
| 1998 | <i>i) Institute of Molecular Medicine, University of Oxford
ii) The Raine Institute, UCL, London
iii) Centre de Biochimie, CNRS, Nice, France
iv) First European Conference of Bone Morphogenetic Proteins, Invited Speaker, Zagreb, Croatia
v) Creative Biomolecules, Boston, MA</i> |
| 1999 | <i>i) Nephrology Division, Albert Einstein College of Medicine, NY
ii) Nephrology Division, Jefferson University, Philadelphia
iii) Nephrology Division, Boston Medical Center
iv) Forsyth Dental Center, Boston
v) Invited Lecture, American Society of Nephrology, Toronto</i> |
| 2000 | <i>i) Nephrology Division, Northwestern University, Chicago
ii) Genetics Institute, Boston</i> |

- 2002
- i) Georgetown University School of Medicine, Washington DC
 - ii) National Institutes of Health, (Yellow Calendar Series) Bethesda, MD
 - iii) National Cancer Institute (Fellowship Office), “Integrating research and mentorship”. Bethesda, MD
 - iv) State of the Art Lecture, American College of Rheumatology, New Orleans
- 2003
- Laboratory of Comparative Carcinogenesis, National Cancer Institute, Frederick
- 2004
- National Institutes of Health, (Yellow Calendar Series) Bethesda, MD
- 2006
- i) Pulmonary Sciences & Critical Care University of Colorado Health Sciences Center, Denver, Colorado
 - ii) National Jewish Hospital, Denver Colorado
- 2007
- i) Visiting Professor, Department of Neonatology, University of Utah, Salt Lake City
 - ii) Visiting Professor, Department of Pharmacology, Uniformed Services University of Health Sciences, Bethesda, MD
- 2008
- i) Nephrology Institute, Manchester Royal Infirmary, England*
 - ii) Department of Medicine, Cambridge University, England*
 - iii) Keynote Speaker, 2008 Symposium on Renin-Angiotensin, Nephrology Research Institute, Fudan University, Shanghai, China*
 - iv) Department of Physiology, Beijing Medical Center, China*
 - v) Departments of Physiology and Medicine, Tulane University (Hypertension and Renal Research Conference and Renal Grand Round)
 - vi) American Society of Nephrology, Basic Science Symposium, “Fate Mapping in the Developing Kidney”, Invited Speaker
- 2009
- i) Invited Speaker, Modern trends in BMP signaling 2009, 7th International BMP Workshop, Berlin, Germany*
 - ii) Invited Speaker Regeneron Pharmaceuticals, Tarrytown, NY
- 2010
- Invited Speaker: 11th International Workshop on Developmental Nephrology, New York
- 2011
- Invited Speaker: 9th International HHT Scientific Conference, Antalya, Turkey*
- 2012
- i) Department of Molecular and Cellular Biology, Roswell Park Cancer center, University of Buffalo
 - ii) Invited Speaker: North American Vascular Biology Organization-2012 Vasculata, Nashville
 - iii) Invited Speaker, BMP signaling in Development and Disease 2012, 9th International BMP Workshop, Lake Tahoe, CA
- 2013
- Visiting Professor, Department of Biological Sciences, University of Pittsburgh
- 2015
- i) Visiting Professor, Department of Developmental Biology, University of Pittsburgh
 - ii) Invited Speaker, 5th Annual AKI Symposium, Renal and Electrolyte Division and Center for Critical Care Nephrology, University of Pittsburgh
 - iii) Visiting Professor, Vascular Biology Center, Georgia Regents University
 - iv) *VIB Center for the Biology of Disease, Catholic University of Leuven, Belgium*
 - v) Invited Speaker, AHA Scientific Sessions, Orlando, Florida
- 2016
- Invited Speaker, American Society of Nephrology Annual Scientific Meeting, Chicago

2017

- i) Invited Speaker, AKI Symposium (22nd International Conferences on Advances in Critical Care Nephrology), San Diego
- ii) Invited Speaker, American Thoracic Society, Grover Conference on Endothelium in vascular pathobiology and lung vascular disease, Colorado (September 2017)
- ii) Invited Speaker, American Society of Nephrology Annual Scientific Meeting, New Orleans (November 2017)